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Abstract 
Background:                                                                                                                      
Asparaginase is an important component of pediatric acute lymphoblastic leukemia therapy. 
Unfortunately, this treatment is hampered by hypersensitivity reactions. In general, allergies 
cause complete inactivation of the drug, regardless of the severity. However, we report atypical 
allergic reactions without inactivation of asparaginase, here called allergic-like reactions.                                                                                         
Procedure:                                                                                                                                         
Patients with an allergic-like reaction, who were treated according to the Dutch Childhood 
Oncology Group ALL-11 or the CoALL 08-09 protocol, were described. The reactions were 
identified by continuous measurement of asparaginase activity levels. Characteristics, including 
timing of occurrence, symptoms, grade and the presence of anti-asparaginase antibodies, were 
compared to those of real allergies.                                                                                                              
Results:                                                                                                                                   
Fourteen allergic-like reactions occurred in nine patients. Five reactions were to 
PEGasparaginase and nine to Erwinia asparaginase. Allergic-like reactions occurred relatively 
late after the start of infusion compared to real allergies. Antibodies were absent in all but one 
patient with an allergic-like reaction while they were detected in all patients with a real allergy. 
Symptoms and grade did not differ between the groups. Asparaginase was continued with the 
same formulation in six patients of whom four finished treatment with adequate activity levels.                                                                                                                                
Conclusions:                                                                                                                                       
In conclusion, allergic-like reactions occur relatively late and without antibodies. Despite these 
clinical differences, allergic-like reactions can only be distinguished from real allergies by 
continuously measuring asparaginase activity levels. If clinically tolerated, formulations should 
not be switched in case of allergic-like reactions. Moreover, failure to recognize these reactions 
may lead to a less favorable prognosis if second line asparaginase therapy is terminated 
unnecessarily. 
 
 
 
 
 
 
 
Introduction 
Asparaginase is one of the key components of childhood acute lymphoblastic leukemia (ALL) 
therapy as intensive dosing-schedules improve event free survival with 10-15%. [1-7] 
Unfortunately, asparaginase treatment is hampered by hypersensitivity reactions like clinical 
allergies and silent inactivation, which neutralize asparaginase completely.[8] In case of silent 
inactivation, asparaginase is inactivated in absence of clinical symptoms. If asparaginase is 
neutralized due to an allergy or silent inactivation, formulations should be switched to maintain 
effective asparaginase treatment. [9-11] 
Previously, we have studied trough PEGasparaginase activity levels and allergies to asparaginase 
in pediatric ALL. The patients were first treated with several doses of native E. coli asparaginase 
in induction phase. PEGasparaginase was administered in the intensification phase 
approximately 12 weeks after the last native E. coli asparaginase dose. [8] Twenty two percent of 
the patients developed an allergic reaction. Most importantly, all allergic reactions to 
PEGasparaginase resulted in complete neutralization of asparaginase. This was regardless of the 
severity or grade of the reaction and was accompanied by anti-asparaginase antibodies. 
Premedication with clemastine or hydrocortisone reduced symptoms of the allergy but could not 
prevent neutralization of asparaginase.[8] Ninety percent of the reactions occurred during the 
second PEGasparaginase dose. Interestingly, trough asparaginase activity levels already proved 
to be zero after the first PEGasparaginase dose, meaning asparaginase was already neutralized 
before the allergic reaction occurred. [8]  
Beside these neutralizing hypersensitivity reactions, there seem to be atypical allergic reactions 
to asparaginase, also called allergic-like reactions, not resulting in inactivation of asparaginase. 
In case of these allergic-like reactions, formulations do not have to be switched to maintain 
adequate asparaginase therapy. Moreover, therapy may even be withheld unnecessarily when 
second line asparaginase is terminated prematurely because of it. Therefore it is very important 
to distinguish between real allergies and allergic-like reactions. It is challenging though to 
interpret activity levels after an allergic reaction when infusion is truncated prematurely and only 
part of the dose is administered. Fortunately, the trough asparaginase activity level of the 
preceding dose can be used to evaluate possible neutralization, which can be accomplished by 
continuous therapeutic drug monitoring (TDM). 
In this article we describe allergic-like reactions and compare these reactions to real allergies in 
order to find differences that can be used in clinical practice to distinguish between the two types 
of reactions. 
 
Methods 
Patients and treatment protocols 
Patients with allergic symptoms without asparaginase inactivation were described. These patients 
were treated according to the CoALL 08-09 treatment protocol or the Dutch Childhood 
Oncology Group (DCOG) ALL-11 protocol, in multiple pediatric oncology centers. These 
protocols are currently open for inclusion and data are not complete yet. Therefore, the frequency 
of allergies and allergic-like reactions is not available at this time. As a comparison, we used all 
patients with an allergy and asparaginase inactivation from the Sophia Children’s Hospital, 
Rotterdam, the Netherlands, who were treated according to the DCOG ALL-10 protocol and 
were partially described earlier.[8] Use of data from the enrolled patients was approved by the 
Institutional Review Board.  
The CoALL 08-09 protocol contained three or four PEGasparaginase doses in the intensification 
phase and one or two in the reinduction phase (2,500 IU/m
2
 ) after an asparaginase-free interval 
of approximately 4 weeks. The doses were administered intravenously over two hours: ten 
percent of the dose during the first hour, the remaining during the second.  Asparaginase activity 
levels were measured to detect silent inactivation. 
The DCOG ALL-11 protocol included three doses of PEGasparaginase in induction and, after an 
interval of approximately 12 weeks, 14 doses in the intensification and maintenance phase. After 
three doses of 1,500 IU/m
2
, TDM was used to individualize the doses based on trough levels.  
Patients who were treated according to the DCOG ALL-10 protocol received eight doses of 
5,000 IU/m
2 
native E. coli asparaginase in induction and 15 PEGasparaginase doses (2,500 
IU/m
2
 biweekly) in the intensification and maintenance phase, also after an asparaginase-free 
interval of approximately 12 weeks. Trough PEGasparaginase activity levels were measured for 
research purposes.  
In both the DCOG ALL-10 and ALL-11 protocol, asparaginase was administered intravenously 
over one hour. In case of allergy or silent inactivation, patients were switched to 20,000 IU/m
2 
Erwinia asparaginase three times a week. TDM was used to adjust the dose schedule for Erwinia 
asparaginase in the DCOG ALL-11 protocol. Erwinia asparaginase was administered 
intravenously over one hour. Asparaginase treatment was terminated when patients developed a 
hypersensitivity reaction to the latter formulation as well. 
 
Classification and description of allergic reactions 
Allergic reactions were classified as either ‘real’ or allergic-like, based on whether they were 
accompanied by asparaginase inactivation. An allergic reaction was considered real if trough 
levels of the preceding dose were already zero before administration of the reaction-inducing 
dose. In case of allergic-like reactions, asparaginase activity levels were measurable (> lower 
limit of quantitation) just prior to or after the reaction-inducing doses. 
When symptoms of an allergic reaction occurred, the following characteristics were described: 
asparaginase activity levels, time of occurrence, symptoms, further treatment and the presence of 
anti-asparaginase antibodies. Allergic and allergic-like reactions were graded according to the 
Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.  
 
Asparaginase activity analysis and anti-asparaginase antibody assay 
Asparaginase activity levels were measured based on the L-aspartic β-hydroxamate (AHA) 
assay.[12] AHA is hydrolyzed by asparaginase to L-aspartic acid and hydroxylamine. 
Hydroxylamine (20 μL) was diluted with 8-hydroxiquinoline for condensation and oxidation and 
was quantified by photometric detection at 690 nm. Trough PEGasparaginase activity levels 
were measured two weeks after administration and were considered adequate when >100 IU/L. 
Trough Erwinia asparaginase activity levels were measured 48 or 72 hours after administration 
and were also considered adequate when >100 IU/L.  
Antibodies against the different asparaginase formulations were determined by enzyme-linked 
immunosorbent assays (ELISA) as described earlier.[8]   
 
Statistical analysis 
The data was analysed with the software package IBM SPSS Statistics (IBM Corp, Armonk, 
New York, USA) version 21.0 for Windows. Time of occurrence of the reactions after the start 
of infusion and presence of anti-asparaginase antibodies  were analysed by non-parametric tests. 
Symptoms were analysed using the Fisher’s exact test. A p-value <0.05 was considered 
statistically significant.  
 
Results 
Fourteen allergic-like reactions occurred in nine patients (table I). Five reactions were to 
PEGasparaginase, the remaining nine to Erwinia asparaginase. As a comparison, we describe 15 
patients with a real allergic reaction to asparaginase (table II).  
 
Asparaginase activity levels 
Asparaginase activity levels are described in table I. Nine levels were obtained just prior to the 
allergy-inducing dose, five were measured after the reaction. In patients number one and two, 
infusion was not stopped after the allergic-like reaction. Both patients had adequate trough 
PEGasparaginase activity levels after this dose (137 and 749 IU/L respectively). Patient number 
three, who received approximately one-third of the individualized dose (700 IU/m
2
), had an 
asparaginase activity level of 83 IU/L one week after the reaction to PEGasparaginase.  
Most patients had adequate Erwinia asparaginase trough levels after a dose interval of 48 hours. 
Only patient number six had an asparaginase activity level of 32 IU/L just before the reaction-
inducing dose. Asparaginase therapy was permanently discontinued  after this reaction. Patient 
number seven had inadequate asparaginase activity levels after each 72-hour dose interval. 
However, after increasing the dose frequency to a 48-hour schedule, asparaginase activity levels 
were adequate. 
All patients with a real allergic reaction already had asparaginase activity levels of zero prior to 
the reaction (table II). Since the majority of the reactions occurred almost immediately after start 
of infusion, which was stopped directly, asparaginase activity levels after the reaction would not 
have been informative and were therefore not measured. However, in patients number 11 and 12, 
trough activity levels after the reaction were available and were both zero.  
 
Anti-asparaginase antibodies 
Anti-asparaginase antibodies were not measured in patients number one and two. The other three 
allergic-like reactions to PEGasparaginase were not accompanied by antibodies against native E. 
coli asparaginase or PEGasparaginase (table I). Antibodies were also absent in all patients with 
an allergic-like reaction to Erwinia asparaginase, except for patient number seven. 
In contrast, all 15 patients with a real allergy to PEGasparaginase had detectable antibodies 
against both  PEGasparaginase and native E. coli asparaginase, which was significantly more 
frequent than in patients with an allergic-like reaction (p=0.001).  
 
Clinical symptoms 
Clinical characteristics are described in table I for the allergic-like reactions, in table II for the 
real allergies and summarized in table III. The median CTCAE grade was grade two in both 
allergic and allergic-like reactions. Four out of the 14 allergic-like reactions were grade one, the 
grade of one reaction is unknown and the remaining nine were grade two. All real allergic 
reactions were grade two.  The type of reactions, i.e. a) symptoms of rash, oedema, itchiness or 
urticaria, b) pulmonary symptoms and c) gastro-intestinal symptoms,  did not differ between 
patients with an allergic or allergic-like reaction (table III).  
Allergic-like reactions occurred significantly later after the start of infusion (median: 29 minutes, 
25-75 percentile: 12-47 minutes) compared to real allergic reactions (median 2 minutes, 25-75 
percentile: 1-5 minutes) (p<0.001).  Patient number two developed an allergic-like reaction 24 
hours after administration. It could be questioned if this reaction was associated with the 
asparaginase infusion. Excluding this case, the allergic-like reactions occurred after a median of 
27 minutes (25-75 percentile: 11-42 minutes) (p<0.001).  
Further treatment 
In three out of five patients with an allergic-like reaction to PEGasparaginase (patients number 
one, two and four), the drug was successfully continued without new allergic-like reactions. The 
activity levels were adequate in patient number four but not measured in the other two patients. 
In  the two other patients (patients number three and five), formulations were switched to 
Erwinia asparaginase directly after the reaction. 
In two out of five patients with an allergic-like reaction to Erwinia asparaginase (patients number 
five and six), the drug was permanently stopped directly after the reaction. In two patients 
(patients number eight and nine), the drug was continued initially but was finally terminated after 
one or more subsequent allergic or allergic-like reactions. Patient number seven successfully 
completed the Erwinia asparaginase doses with adequate levels, although three allergic-like 
reactions occurred in total.  
 
Discussion 
In this article, allergic-like reactions to asparaginase were reported and compared to real 
allergies.  It is important to distinguish between these types of reactions because if allergic-like 
reactions are incorrectly interpreted as real allergies, asparaginase formulations will be switched 
or terminated unnecessarily. 
 
Asparaginase activity levels are difficult to interpret when measured after an allergic reaction. A 
low asparaginase activity level could be caused by either neutralizing antibodies or premature 
termination of the dose. However, our patients with real allergic reactions already show complete 
asparaginase inactivation of the previous dose. Therefore distinction between allergic-like and 
real allergic reactions can be made based on the trough level of the preceding dose.  
 
The correlation between hypersensitivity reactions and anti-asparaginase antibodies has been 
frequently studied. To date, four groups can be distinguished. The first group contains patients 
with an allergic reaction, accompanied by the presence of anti-asparaginase antibodies. [8,9,13] 
Patients in the second group neutralize asparaginase in absence of clinical symptoms, so called 
silent inactivation, and also have antibodies against asparaginase.[8] The third group includes 
patients without a hypersensitivity reaction to or neutralization of asparaginase, but with anti-
asparaginase antibodies which has been  reported in 6-38% of patients treated with 
asparaginase.[8,13,14] The fourth group contains patients who have allergic symptoms without 
development of anti-asparaginase antibodies. This was described by Liu et al. in 4-7% of the 
patients and by Panosyan et al. in 10%.[9,13] Unfortunately, both studies did not describe 
asparaginase activity and these reactions might have been allergic-like reactions. In our cohort, 
all patients with a real allergic reaction had anti-asparaginase antibodies whereas antibodies were 
absent in all but one of the allergic-like patients (p=0.001). Thus, the occurrence of allergic 
symptoms in absence of anti-asparaginase antibodies may indicate an allergic-like reaction, 
without inactivating asparaginase.  
 
Patients with an allergic-like reaction cannot be distinguished from allergic reactions based on 
clinical symptoms or allergy grade. The only clinical difference between allergic-like reactions 
and real allergies,  appeared to be the time of occurrence. In our cohort, allergic-like reactions 
occurred significantly later after the start of administration. Most real allergic reactions occurred 
within minutes after start,  though two patients developed a real  allergic reaction after more than 
10 minutes. Thus a late timing of the reaction after the start infusion is a strong indication of an 
allergic-like reaction but distinction cannot be made conclusively.  
 
The mechanism of allergic-like reactions is unclear. Based on a review recently published by 
Asselin, it can be discussed that allergic-like reactions are related to the non-antibody mediated 
hypersensitivity reactions that were described. Thus, the allergic-like reactions might be 
explained by a rapid increase of ammonia levels caused by the administration of asparaginase. 
Symptoms of this ammonia peak include nausea, vomiting and rash.[15] Although these 
symptoms overlap with part of the allergic-like symptoms, half of the patients with an allergic-
like reaction had oedema, dyspnoea or urticaria, which cannot be explained by 
hyperammonemia. On the other hand, Tong et al. have shown that ammonia levels are higher 
after Erwinia asparaginase therapy than after PEGasparaginase therapy, probably caused by the 
higher glutaminase activity of Erwinia asparaginase.[16] This can explain why allergic-like 
reactions occur relatively frequent during Erwinia asparaginase treatment.   Unfortunately, 
ammonia levels were not measured in our cohort but their role in the development and 
identification of allergic-like reactions should be studied. 
 
In conclusion, we describe allergic-like reactions to PEGasparaginase and Erwinia asparaginase, 
not leading to inactivation of the drug.  These reactions occur relatively late after the start of 
infusion and anti-asparaginase antibodies are absent in the far majority of these patients, but 
distinction can only be made when asparaginase activity levels are monitored continuously, as it 
is done with therapeutic drug monitoring. Most importantly, patients are able to complete their 
asparaginase treatment with the same formulation if clinically tolerated. Although not useful in 
case of a real allergy,  reducing the infusion rate and administering premedication may prevent 
symptoms  in case of an allergic-like reaction. 
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